Compare Citius Pharmaceuticals Inc (CTXR) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs KraneShares CSI China Internet ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while KraneShares CSI China Internet ETF trades at $24.87 (market cap $4.37B). The key difference: KraneShares CSI China Internet ETF is far larger — about 320.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 13,393,361). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and KraneShares CSI China Internet ETF for 57 Days on average.
| CTXR | KWEB | |
|---|---|---|
Market Cap | $13.62M | $4.37B |
Volume | 132,438 | 13,393,361 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $41.35 |
52-Week Low | $0.48 | $23.63 |
Typical Hold Time | 17 Days | 57 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
KWEB, the KraneShares CSI China Internet ETF, trades at $24.87, up 2.22% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell, while oscillators are neutral. Recent news highlights institutional activity, including a stake reduction by Tidal Investments LLC and an increase by HSBC Holdings PLC, amid ongoing U.S.-China trade dynamics and economic data releases.
The outlook for KWEB is clouded by geopolitical tensions and economic headwinds in China, though corporate profit growth offers a potential catalyst. Key risks include trade policy shifts and weak domestic consumption. Investors should weigh institutional movements against broader market sentiment for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
